HydraMed: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of HydraMed’s website, https://hydramed.com, FDA Establishment Identifier (FEI) 3044021141, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “HydraMed” on the pictured label, suggesting HydraMed is the compounder of those drugs when in fact it is not.”

2. 2

   “2. Your website claims that the compounded drug products it offers are sourced from an “FDA-approved pharmacy.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an “FDA-approved” or “FDA-licensed” designation for pharmacies or outsourcing facilities. Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

hydramed.com returned HTTP 500 on 2026-08-09. The response came from Netlify with x-nf-render-mode: ssr and served the site's own rendered error page, reading "500 Something went wrong! While we fix the server, please reach out to us" above two staffed contact numbers; /weight-loss and /shop both returned 404. A deployment failing to render is not evidence of closure — the error page itself invites contact — so this is recorded as unknown rather than ceased.

Strip out the sales copy and this letter is entirely about provenance: who made the drug, and who is supposed to have vouched for them. Both answers on the page were wrong in the same direction. The vial carried the seller's name rather than the compounder's, and the compounder was described as an "FDA-approved pharmacy" — a status FDA says does not exist for any pharmacy or outsourcing facility, because none of them undergo premarket review. Those two claims work together on a reader. One suggests the company you are buying from made the medicine; the other suggests a regulator signed off on whoever did. Together they close the question of sourcing entirely, which is the question worth keeping open when the same molecule is sold at very different prices by very different operators. The separate practical point is that when we checked, the site would not load at all. That is not evidence the business has closed and we have not recorded it as such — but it is a reason to confirm a seller can actually take and fulfil an order before paying one.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence HydraMed failed to respond.